Biogen Inc Stock Buy Hold or Sell Recommendation
| BIIB Stock | USD 139.44 0.54 0.39% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Biogen Inc is 'Hold'. Macroaxis provides Biogen buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Biogen positions.
Check out Biogen Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Biogen and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Biogen |
Execute Biogen Buy or Sell Advice
The Biogen recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Biogen Inc. Macroaxis does not own or have any residual interests in Biogen Inc or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Biogen's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Biogen Trading Alerts and Improvement Suggestions
| Biogen Inc generated a negative expected return over the last 90 days | |
| Biogen Inc has a poor financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono |
Biogen Returns Distribution Density
The distribution of Biogen's historical returns is an attempt to chart the uncertainty of Biogen's future price movements. The chart of the probability distribution of Biogen daily returns describes the distribution of returns around its average expected value. We use Biogen Inc price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Biogen returns is essential to provide solid investment advice for Biogen.
| Mean Return | -0.17 | Value At Risk | -3.41 | Potential Upside | 2.13 | Standard Deviation | 1.70 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Biogen historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Biogen Stock Institutional Investors
| Shares | T. Rowe Price Associates, Inc. | 2024-12-31 | 1.9 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.8 M | Beutel, Goodman & Company Ltd. | 2024-12-31 | 1.7 M | D. E. Shaw & Co Lp | 2024-12-31 | 1.6 M | Northern Trust Corp | 2024-12-31 | 1.6 M | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 1.5 M | Legal & General Group Plc | 2024-12-31 | 1.2 M | Amundi | 2024-12-31 | 1.2 M | Renaissance Technologies Corp | 2024-12-31 | 1.2 M | Vanguard Group Inc | 2024-12-31 | 16.7 M | Primecap Management Company | 2024-12-31 | 16 M |
Biogen Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (1.6B) | 930.2M | 1.2B | (2.4B) | 1.3B | 1.4B | |
| Free Cash Flow | 3.7B | 3.3B | 1.1B | 1.2B | 2.5B | 1.4B | |
| Depreciation | 457.2M | 487.7M | 518.4M | 494.8M | 673.2M | 358.9M | |
| Other Non Cash Items | (448M) | 1.8B | (1.3B) | 581.2M | 592.2M | 621.8M | |
| Capital Expenditures | 551.8M | 294.9M | 243.2M | 311.4M | 359.8M | 428.4M | |
| Net Income | 4.1B | 1.7B | 3.0B | 1.2B | 1.6B | 1.3B | |
| End Period Cash Flow | 1.3B | 2.3B | 3.4B | 1.0B | 2.4B | 2.5B | |
| Change To Inventory | (316.3M) | (462.4M) | (320.2M) | (130.9M) | (273.8M) | (260.1M) | |
| Investments | (29.9M) | (309.8M) | 1.6B | (4.1B) | (799.2M) | (759.2M) | |
| Change Receivables | 68.8M | 2.8M | 324.8M | (203.4M) | (233.9M) | (245.6M) | |
| Change To Netincome | 254.9M | 673.6M | 743.3M | (1.5B) | (1.3B) | (1.3B) |
Biogen Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Biogen or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Biogen's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Biogen stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.16 | |
β | Beta against Dow Jones | 0.24 | |
σ | Overall volatility | 1.70 | |
Ir | Information ratio | -0.04 |
Biogen Volatility Alert
Biogen Inc exhibits very low volatility with skewness of -0.59 and kurtosis of 0.7. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biogen's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biogen's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Biogen Fundamentals Vs Peers
Comparing Biogen's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Biogen's direct or indirect competition across all of the common fundamentals between Biogen and the related equities. This way, we can detect undervalued stocks with similar characteristics as Biogen or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Biogen's fundamental indicators could also be used in its relative valuation, which is a method of valuing Biogen by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Biogen to competition |
| Fundamentals | Biogen | Peer Average |
| Return On Equity | 0.1 | -0.31 |
| Return On Asset | 0.0529 | -0.14 |
| Profit Margin | 0.17 % | (1.27) % |
| Operating Margin | 0.22 % | (5.51) % |
| Current Valuation | 24.74 B | 16.62 B |
| Shares Outstanding | 146.38 M | 571.82 M |
| Shares Owned By Insiders | 0.20 % | 10.09 % |
| Shares Owned By Institutions | 94.39 % | 39.21 % |
| Number Of Shares Shorted | 3.88 M | 4.71 M |
| Price To Earning | 14.83 X | 28.72 X |
| Price To Book | 1.23 X | 9.51 X |
| Price To Sales | 2.11 X | 11.42 X |
| Revenue | 9.68 B | 9.43 B |
| Gross Profit | 7.37 B | 27.38 B |
| EBITDA | 3 B | 3.9 B |
| Net Income | 1.63 B | 570.98 M |
| Cash And Equivalents | 4.91 B | 2.7 B |
| Cash Per Share | 34.10 X | 5.01 X |
| Total Debt | 6.63 B | 5.32 B |
| Debt To Equity | 0.52 % | 48.70 % |
| Current Ratio | 2.49 X | 2.16 X |
| Book Value Per Share | 114.65 X | 1.93 K |
| Cash Flow From Operations | 2.88 B | 971.22 M |
| Short Ratio | 2.33 X | 4.00 X |
| Earnings Per Share | 11.18 X | 3.12 X |
| Price To Earnings To Growth | 6.24 X | 4.89 X |
| Target Price | 201.18 | |
| Number Of Employees | 7.61 K | 18.84 K |
| Beta | 0.012 | -0.15 |
| Market Capitalization | 20.41 B | 19.03 B |
| Total Asset | 28.05 B | 29.47 B |
| Retained Earnings | 19.26 B | 9.33 B |
| Working Capital | 1.93 B | 1.48 B |
Note: Acquisition by Mantas Jesus B of 1340 shares of Biogen subject to Rule 16b-3 [view details]
Biogen Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Biogen . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.0154 | |||
| Daily Balance Of Power | (0.25) | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 139.72 | |||
| Day Typical Price | 139.62 | |||
| Market Facilitation Index | 2.17 | |||
| Price Action Indicator | (0.55) | |||
| Period Momentum Indicator | (0.54) |
About Biogen Buy or Sell Advice
When is the right time to buy or sell Biogen Inc? Buying financial instruments such as Biogen Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Biogen in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Most Shorted Equities Thematic Idea Now
Most Shorted Equities
Dynamically calculated list of top equities currently trending upward via a buy-out by investors. The Most Shorted Equities theme has 147 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Most Shorted Equities Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Biogen Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.063 | Earnings Share 11.18 | Revenue Per Share | Quarterly Revenue Growth 0.029 | Return On Assets |
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.